You just read:

OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999

News provided by

OBI Pharma, Inc.

Sep 03, 2019, 05:00 ET